Last reviewed · How we verify
PIPERACILLIN AND TAZOBACTAM (PIPERACILLIN,TAZOBACTAM)
PIPERACILLIN AND TAZOBACTAM (generic name: PIPERACILLIN,TAZOBACTAM) is a drug developed by EUGIA PHARMA. It is currently FDA-approved.
Piperacillin and tazobactam is a combination antibiotic used to treat various infections, including severe burns, febrile urinary tract infections, and infections in intensive care. It works by inhibiting bacterial penicillin-binding proteins, which are essential for bacterial cell wall formation.
At a glance
| Generic name | PIPERACILLIN,TAZOBACTAM |
|---|---|
| Sponsor | EUGIA PHARMA |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- PHARMACY BULK PACKAGE-NOT FOR DIRECT INFUSION
Common side effects
- Diarrhea
- Diarrhea
- Headache
- Constipation
- Nausea
- Insomnia
- Constipation
- Rash
- Pruritus
- Vomiting
- Dyspepsia
- Fever
Serious adverse events
- Allergic reactions
- Anaphylaxis
- Pseudomembranous colitis
- Thrombophlebitis
- Hypotension
- Renal failure
- Rash (bullous)
Key clinical trials
- Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (Phase 3)
- A Prospective Randomised Controlled Non-inferiority Study to Evaluate the Effectiveness and Safety (APRES) of Non-operative Management in Children With Acute Uncomplicated Appendicitis (NA)
- A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Includin (Phase 3)
- Comparison of the Nephrotoxicity of Vancomycin in Combination With Piperacillin/Tazobactam or Other Beta-lactams in Critically Ill Patients: A Retrospective, Multicenter Study in China (N/A)
- A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti (Phase 3)
- Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Haematologic Patients: a Randomised, Multicentre, Open-label, Superiority Clinical Trial (BEATLE) (Phase 4)
- An Open-label, Randomized Study Comparing the Efficacy and Safety of Piperacillin/Tazobactam and Ampicillin/Sulbactam Administered Intravenously in the Empirical Treatment of Foot Infections in Diabet (Phase 4)
- A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability, of Ertapenem Versus Piperacillin/Tazobactam in the Tr (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIPERACILLIN AND TAZOBACTAM CI brief — competitive landscape report
- PIPERACILLIN AND TAZOBACTAM updates RSS · CI watch RSS
- EUGIA PHARMA portfolio CI
Frequently asked questions about PIPERACILLIN AND TAZOBACTAM
What is PIPERACILLIN AND TAZOBACTAM?
Who makes PIPERACILLIN AND TAZOBACTAM?
What is the generic name of PIPERACILLIN AND TAZOBACTAM?
What development phase is PIPERACILLIN AND TAZOBACTAM in?
What are the side effects of PIPERACILLIN AND TAZOBACTAM?
Related
- Manufacturer: EUGIA PHARMA — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing